Samsung Biologics Signs Pharmaceutical Contract Manufacturing Agreement Worth 439.4 Billion KRW

[Asia Economy Reporter Kang Nahum] Samsung Biologics announced on the 5th that it has signed a contract for contract manufacturing of pharmaceuticals worth 439.37099 billion KRW with the British pharmaceutical company GSK (GlaxoSmithKline Trading Services Limited).

This corresponds to 62.62% of the company's recent sales. The contract period is from April 9 to December 31, 2022.